GET DAILY SIGNALSOlema Pharmaceuticals (OLMA) Readies Q3 2026 Earnings Report With Pipeline in Focus
Key Takeaways
- Olema Pharmaceuticals (OLMA) is set to report third-quarter 2026 results for the period ended September 30, 2026, on or around November 9–10, 2026.
- Wall Street expects a wider net loss of roughly $0.64 per share, compared with a $0.49 loss in the prior-year quarter, as late-stage trial spending accelerates.
- As a clinical-stage biotech, Olema remains effectively pre-revenue, so investors will watch pipeline updates more closely than the income statement.
- Attention is focused on the OPERA-01 and OPERA-02 Phase 3 trials of palazestrant and early data for OP-3136, a KAT6 inhibitor.
- The prior quarter (Q2 2026) missed estimates with a $0.61 loss, adding a cautious tone heading into this report.
- For more context, visit our pages for Major News, Today's Price Move, Price Targets, and Forecast on Olema Pharmaceuticals.
- You can also explore Trending AI Robots to discover AI-driven trading strategies across the market.
Earnings Context and Pipeline Focus
Olema Pharmaceuticals, also known as Olema Oncology, is a clinical-stage biopharmaceutical company developing therapies for women's cancers. Its lead candidate, palazestrant, is a complete estrogen receptor (ER) antagonist in two pivotal Phase 3 trials for ER-positive, HER2-negative metastatic breast cancer. Because the company generates essentially no product revenue, quarterly earnings serve primarily as a checkpoint on spending and cash runway, while the real value driver is clinical progress. With the OPERA-01 monotherapy readout expected in the first quarter of 2027, each report is scrutinized for signs of trial momentum, enrollment trends, and any shifts in timelines that could reshape the investment thesis. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
What the Numbers Are Expected to Show
Consensus estimates point to a net loss of approximately $0.64 per share for the third quarter of 2026, according to data from MarketWatch and FactSet, though some aggregators cluster near $0.60. That compares with a $0.49 loss in the same quarter a year ago, when Olema reported a net loss of $42.2 million and ended the period with $329.0 million in cash and marketable securities. Revenue expectations are negligible, reflecting the company's pre-commercial status. The widening expected loss largely reflects higher research and development (R&D) spending tied to the OPERA-01 and OPERA-02 late-stage trials and the advancement of OP-3136. In Q2 2026, Olema posted a $0.61 loss, missing the roughly $0.55 consensus, with R&D expenses climbing to $57.8 million. From what I see, this pattern of rising costs is typical for companies advancing multiple late-stage studies at once.
Market Reaction and Investor Sentiment
Sentiment heading into this report is cautious but not bearish. Olema shares have been volatile in recent months, and the stock's reaction is likely to hinge less on the loss figure itself and more on any commentary around trial timelines, data-readout schedules, and cash runway. The Q2 2026 miss underscores how operating-expense growth can outpace estimates as pivotal studies accelerate. Analysts maintain an average "Buy" rating with a target price well above current trading levels, but the wide gap between estimates on the loss per share reflects uncertainty about the pace of spending. Key risks include potential delays in the OPERA-01 readout, competitive developments in the oral selective estrogen receptor degrader (SERD) market, and any signal that the company may need additional financing before a pivotal data catalyst. In my view, the focus will remain squarely on execution milestones rather than the headline loss number.
Forward Outlook and Key Factors to Monitor
The most important catalyst on the horizon remains the OPERA-01 Phase 3 readout for palazestrant monotherapy, now expected in the first quarter of 2027. Management commentary on enrollment completion, data maturation, and any interaction with regulators will carry more weight than the quarterly loss figure.
Investors should also monitor the OPERA-02 frontline combination trial, which pairs palazestrant with ribociclib, as well as early safety and efficacy signals for OP-3136, a KAT6 (lysine acetyltransferase 6) inhibitor in Phase 1 development. Combination data expected in the first half of next year could further shape the pipeline narrative.
On the financial side, watch R&D expense trends and the company's cash position, which is widely viewed as sufficient to fund operations through the next major data catalyst. Any indication of accelerated spending or a shift in the expected data timeline would be closely scrutinized. As with most clinical-stage oncology names, the investment case hinges on binary trial outcomes rather than near-term profitability. I’m watching this closely for any updates that could influence positioning ahead of the readout.
Exploring AI Tools for Biotech Research
In my own analysis of clinical-stage names like OLMA, I often turn to Tickeron’s AI Screener to quickly filter peers by volatility, technical patterns, and sector trends. It helps surface comparable opportunities without spending hours on manual screens, which is especially useful when pipeline timelines are the primary driver rather than current earnings. This kind of tool keeps the research process efficient while highlighting broader market context around a specific holding.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
OLMA's Indicator enters downward trend
The Aroon Indicator for OLMA entered a downward trend on November 03, 2026. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 245 similar instances where the Aroon Indicator formed such a pattern. In 221 of the 245 cases the stock moved lower. This puts the odds of a downward move at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 49 of 56 cases where OLMA's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 88%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where OLMA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where OLMA's RSI Indicator exited the oversold zone, 23 of 30 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 77%.
The Momentum Indicator moved above the 0 level on November 06, 2026. You may want to consider a long position or call options on OLMA as a result. In 68 of 84 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 81%.
The Moving Average Convergence Divergence (MACD) for OLMA just turned positive on October 21, 2026. Looking at past instances where OLMA's MACD turned positive, the stock continued to rise in 36 of 43 cases over the following month. The odds of a continued upward trend are 84%.
Following a +8.88% 3-day Advance, the price is estimated to grow further. Considering data from situations where OLMA advanced for three days, in 225 of 268 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
OLMA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 14 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 28 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.490) is normal, around the industry mean (3.498). P/E Ratio (-3.458) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 78 (best 1 - 100 worst), indicating slightly worse than average price growth. OLMA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. OLMA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement